Vagina sarcoma

Summary

Vagina sarcoma (MONDO:0002140) is a cancer. Molecularly, ALK Fusion confers sensitivity to Crizotinib in Vagina Sarcoma (CIViC Level C). A subtype of vaginal cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vagina sarcoma
Mondo ID	MONDO:0002140
DOID	DOID:1901
NCIT	C7737
UMLS	C0238519
MedGen	65971
GARD	0023074
Anatomy (UBERON)	UBERON:0000996
Is cancer (heuristic)	yes

Also known as: sarcoma of the vagina · sarcoma of vagina · vagina sarcoma · vaginal sarcoma

Disease family

This is a subtype of vaginal cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › vaginal cancer › vagina sarcoma

Related subtypes (4): vaginal adenosarcoma, vaginal carcinoma, vaginal germ cell malignant tumor, malignant vaginal mixed epithelial and mesenchymal neoplasm

Subtypes (3): endometrioid stromal sarcoma of the vagina, vagina leiomyosarcoma, vaginal rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
ALK Fusion	Crizotinib	Sensitivity/Response	CIViC C	EID6042